Glioblastoma: Emerging Treatments and Novel Trial Designs

Management of glioblastoma is a clinical challenge since very few systemic treatments have shown clinical efficacy in recurrent disease. Thanks to an increased knowledge of the biological and molecular mechanisms related to disease progression and growth, promising novel treatment strategies are eme...

Full description

Bibliographic Details
Main Authors: Vincenzo Di Nunno, Enrico Franceschi, Alicia Tosoni, Lidia Gatto, Raffaele Lodi, Stefania Bartolini, Alba Ariela Brandes
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
GBM
Online Access:https://www.mdpi.com/2072-6694/13/15/3750
id doaj-941f73dc5f21479aae0a2b3373dd6d7a
record_format Article
spelling doaj-941f73dc5f21479aae0a2b3373dd6d7a2021-08-06T15:20:23ZengMDPI AGCancers2072-66942021-07-01133750375010.3390/cancers13153750Glioblastoma: Emerging Treatments and Novel Trial DesignsVincenzo Di Nunno0Enrico Franceschi1Alicia Tosoni2Lidia Gatto3Raffaele Lodi4Stefania Bartolini5Alba Ariela Brandes6Department of Oncology, AUSL Bologna, Via Altura 3, 40139 Bologna, ItalyDepartment of Oncology, AUSL Bologna, Via Altura 3, 40139 Bologna, ItalyDepartment of Oncology, AUSL Bologna, Via Altura 3, 40139 Bologna, ItalyDepartment of Oncology, AUSL Bologna, Via Altura 3, 40139 Bologna, ItalyIstituto delle Scienze Neurologiche di Bologna, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 40139 Bologna, ItalyDepartment of Oncology, AUSL Bologna, Via Altura 3, 40139 Bologna, ItalyDepartment of Oncology, AUSL Bologna, Via Altura 3, 40139 Bologna, ItalyManagement of glioblastoma is a clinical challenge since very few systemic treatments have shown clinical efficacy in recurrent disease. Thanks to an increased knowledge of the biological and molecular mechanisms related to disease progression and growth, promising novel treatment strategies are emerging. The expanding availability of innovative compounds requires the design of a new generation of clinical trials, testing experimental compounds in a short time and tailoring the sample cohort based on molecular and clinical behaviors. In this review, we focused our attention on the assessment of promising novel treatment approaches, discussing novel trial design and possible future fields of development in this setting.https://www.mdpi.com/2072-6694/13/15/3750glioblastomanewly diagnosed glioblastomarecurrent glioblastomaGBMnew trial design
collection DOAJ
language English
format Article
sources DOAJ
author Vincenzo Di Nunno
Enrico Franceschi
Alicia Tosoni
Lidia Gatto
Raffaele Lodi
Stefania Bartolini
Alba Ariela Brandes
spellingShingle Vincenzo Di Nunno
Enrico Franceschi
Alicia Tosoni
Lidia Gatto
Raffaele Lodi
Stefania Bartolini
Alba Ariela Brandes
Glioblastoma: Emerging Treatments and Novel Trial Designs
Cancers
glioblastoma
newly diagnosed glioblastoma
recurrent glioblastoma
GBM
new trial design
author_facet Vincenzo Di Nunno
Enrico Franceschi
Alicia Tosoni
Lidia Gatto
Raffaele Lodi
Stefania Bartolini
Alba Ariela Brandes
author_sort Vincenzo Di Nunno
title Glioblastoma: Emerging Treatments and Novel Trial Designs
title_short Glioblastoma: Emerging Treatments and Novel Trial Designs
title_full Glioblastoma: Emerging Treatments and Novel Trial Designs
title_fullStr Glioblastoma: Emerging Treatments and Novel Trial Designs
title_full_unstemmed Glioblastoma: Emerging Treatments and Novel Trial Designs
title_sort glioblastoma: emerging treatments and novel trial designs
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2021-07-01
description Management of glioblastoma is a clinical challenge since very few systemic treatments have shown clinical efficacy in recurrent disease. Thanks to an increased knowledge of the biological and molecular mechanisms related to disease progression and growth, promising novel treatment strategies are emerging. The expanding availability of innovative compounds requires the design of a new generation of clinical trials, testing experimental compounds in a short time and tailoring the sample cohort based on molecular and clinical behaviors. In this review, we focused our attention on the assessment of promising novel treatment approaches, discussing novel trial design and possible future fields of development in this setting.
topic glioblastoma
newly diagnosed glioblastoma
recurrent glioblastoma
GBM
new trial design
url https://www.mdpi.com/2072-6694/13/15/3750
work_keys_str_mv AT vincenzodinunno glioblastomaemergingtreatmentsandnoveltrialdesigns
AT enricofranceschi glioblastomaemergingtreatmentsandnoveltrialdesigns
AT aliciatosoni glioblastomaemergingtreatmentsandnoveltrialdesigns
AT lidiagatto glioblastomaemergingtreatmentsandnoveltrialdesigns
AT raffaelelodi glioblastomaemergingtreatmentsandnoveltrialdesigns
AT stefaniabartolini glioblastomaemergingtreatmentsandnoveltrialdesigns
AT albaarielabrandes glioblastomaemergingtreatmentsandnoveltrialdesigns
_version_ 1721218828214468608